摘要
Abstract
Objective:To evaluate the changes of tumor-related markers in patients with non-small cell lung cancer(NSCLC)by Pemetrexed combined with Cisplatin chemotherapy regimen,and to provide more accurate and comprehensive guidance for clinical treatment.Method:A total of 80 NSCLC patients admitted to Suzhou Yongding Hospital,the First Affiliated Hospital of Qiqihar Medical College and Suzhou BOE Hospital from October 2021 to June 2023 were selected as study samples.Patients were divided into control group(n=40)and observation group(n=40)by random number table method.The control group was given Paclitaxel for Injection(Albumin Bound)combined with Cisplatin chemotherapy,and the observation group was given Pemetrexed combined with Cisplatin chemotherapy.Serum tumor markers,nutritional status,immune function and quality of life[functional assessment of cancer therapy-lung(FACT-L)]were compared between the two groups before treatment and after 2 cycles of treatment.Result:After 2 cycles of treatment,the levels of carcinoembryonic antigen(CEA),neurone-specific enolase(NSE),cytokeratin 19 fragment(Cyfra 21-1)and carbohydrate antigen 125(CA125)in both groups were decreased compared with before treatment,and the observation group were lower than those of the control group(P<0.05).After 2 cycles of treatment,CD8+levels in both groups increased compared with before treatment,but which was lower in observation group compared with control group,CD4+and CD4+/CD8+levels decreased compared with before treatment,but which was higher in observation group compared with control group(P<0.05).After 2 cycles of treatment,FACT-L scores in observation group were higher than those in control group,the differences were statistically significant(P<0.05).Conclusion:Pemetrexed combined with Cisplatin chemotherapy can effectively reduce the tumor markers in the serum of patients with NSCLC,and improve the immune function of patients,thus improving the quality of life of patients.关键词
培美曲塞/顺铂/化疗/非小细胞肺癌/血清肿瘤标志物Key words
Pemetrexed/Cisplatin/Chemotherapy/Non-small cell lung cancer/Serum tumor markers
